Literature DB >> 30575900

FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway.

Y-Z Luo1, P He, M-X Qiu.   

Abstract

OBJECTIVE: To investigate the effect of highly-expressed FOSL1 on the tumorigenesis and metastasis of prostate cancer. PATIENTS AND METHODS: Researches were carried out in human prostate cancer tissues and cell lines. In prostate cancer tissues, the expression of FOSL was detected by immunohistochemistry. In vitro cell line experiments, we constructed a prostate cancer cell model with FOSL1 stable knockdown and tested cell proliferation and metastasis before and after knockdown of FOSL1. Finally, the epithelial-mesenchymal transition (EMT) markers before and after interference of FOSL1 were also analyzed.
RESULTS: FOSL1 was confirmed to have a high expression in prostate cancer. Transwell experiments demonstrated that FOSL1 could enhance prostate cancer metastasis, while in vivo experiments revealed an accelerated progression of prostate cancer caused by FOSL1. In addition, Western blot analysis revealed an elevated level of N-cadherin and Snail1 and a reduced level of E-cadherin that was induced by FOSL1.
CONCLUSIONS: FOSL1 can promote the occurrence and progression of prostate cancer by altering the EMT process of cells.

Entities:  

Year:  2018        PMID: 30575900     DOI: 10.26355/eurrev_201812_16624

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

2.  Identification and Validation of a Six Immune-Related Genes Signature for Predicting Prognosis in Patients With Stage II Colorectal Cancer.

Authors:  Xianzhe Li; Minghao Xie; Shi Yin; Zhizhong Xiong; Chaobin Mao; Fengxiang Zhang; Huaxian Chen; Longyang Jin; Ping Lan; Lei Lian
Journal:  Front Genet       Date:  2021-05-04       Impact factor: 4.599

3.  Signature identification of relapse-related overall survival of early lung adenocarcinoma after radical surgery.

Authors:  Peng Han; Jiaqi Yue; Kangle Kong; Shan Hu; Peng Cao; Yu Deng; Fan Li; Bo Zhao
Journal:  PeerJ       Date:  2021-08-05       Impact factor: 2.984

Review 4.  Epithelial-mesenchymal transition and its transcription factors.

Authors:  Pallabi Debnath; Rohit Singh Huirem; Paloma Dutta; Santanu Palchaudhuri
Journal:  Biosci Rep       Date:  2022-01-28       Impact factor: 3.840

5.  Silencing of FOS-like antigen 1 represses restenosis via the ERK/AP-1 pathway in type 2 diabetic mice.

Authors:  Chaoxi Zhou; Fujun Wang; Hongfang Ma; Na Xing; Lin Hou; Yaping Du; Haixia Ding
Journal:  Diab Vasc Dis Res       Date:  2021 Nov-Dec       Impact factor: 3.291

6.  FOSL1 knockdown ameliorates DSS-induced inflammation and barrier damage in ulcerative colitis via MMP13 downregulation.

Authors:  Lizhuan Ma; Xiujing Zhang; Chao Zhang; Bingxu Hou; Hongtao Zhao
Journal:  Exp Ther Med       Date:  2022-07-01       Impact factor: 2.751

7.  MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma.

Authors:  Wei Wang; Wei Liu; Jing Xu; Hongze Jin
Journal:  Front Genet       Date:  2022-08-17       Impact factor: 4.772

8.  SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.

Authors:  Chao Dai; Jonathan P Rennhack; Taylor E Arnoff; Maneesha Thaker; Scott T Younger; John G Doench; August Yue Huang; Annan Yang; Andrew J Aguirre; Belinda Wang; Evan Mun; Joyce T O'Connell; Ying Huang; Katherine Labella; Jessica A Talamas; Ji Li; Nina Ilic; Justin Hwang; Andrew L Hong; Andrew O Giacomelli; Ole Gjoerup; David E Root; William C Hahn
Journal:  Cell Rep       Date:  2021-07-27       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.